基于诊断分析的个体化痛泻方是否更有效减轻IBS症状:一项随机对照试验
该随机对照试验将IBS患者按1:1:1分为痛泻方组、安慰剂组和匹维溴铵组,每日三次治疗4周,痛泻方组依据中医辨证(肝郁气滞、肝火旺盛、脾虚、肾虚等)给予个体化配方。主要终点为腹痛和Bristol粪便评分的显著降低,结果显示全人群粪便性状改善人数显著多于疼痛缓解人数(p<0.001),但亚组3无显著差异,提示个体化配方对获得最佳结局具有重要意义。
要点
- 个体化痛泻方基于中医辨证分型治疗IBS,亚组结局可能与全人群不同。
- 全人群中粪便性状改善人数显著多于疼痛缓解人数(p<0.001)。
- 研究识别出多种活性成分及其缓解IBS症状的机制。
核心结论
- 亚组人群的结局可能与全人群不同,表明个体化配方对实现最佳结局具有重要意义。
- 研究识别出的活性成分和创新机制可作为开发新IBS药物的候选,并分别用于管理IBS。
研究设计与样本
- 随机对照试验,患者按1:1:1随机分为痛泻方组、安慰剂组和匹维溴铵组,每日三次治疗4周。
- 痛泻方组基于中医辨证诊断给予个体化配方,包括基本型IBS、肝郁气滞型、肝火旺盛型、脾虚型、肾虚型及其他(组1-6)。
- 主要终点为腹痛和Bristol粪便评分的显著降低;次要终点为疼痛和排便频率、腹部不适及其频率的降低。
主要发现
- 全人群中粪便性状改善的患者数显著多于疼痛缓解的患者数(p<0.001),但亚组3无显著差异(p>0.05)。
- 全人群中排便频率减少的患者数显著多于疼痛频率减少的患者数(p<0.001),但亚组1、3、4和6无显著差异(p>0.05)。
- 识别出多种活性成分及其缓解IBS症状的作用机制。
临床怎么用
- 临床可基于中医辨证分型为IBS患者制定个体化痛泻方,以追求更优结局。
- 关注个体化配方中识别出的活性成分及其缓解IBS症状的机制,作为潜在治疗参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine the efficacy and safety ofpersonalized tongxie formulas; to decrease type II errors to minimum. METHODS: Patients were randomized (1:1:1) into three groups given tongxie, placebo, or pinaverium 3 times daily for 4 weeks. Patients in the tongxie group were treated with personalized formulas based on TCM differential diagnosis, i.e., basic type of IBS, IBS due to liver depression and qi stagnation, excess heat in the liver, deficient spleen function, deficient kidney function, and others (groups 1-6). Primary endpoints were significantly greater reductions in abdominal pain and Bristol stool score. Secondary endpoints were reductions in pain and stool frequencies and abdominal discomfort and its frequency. RESULTS: There were significantly more patients whose stool consistencies were improved than pains were relieved in the entire population (p < 0.001), but there was no significantly difference in subpopulation group 3 (p > 0.05). There were significantly more patients whose stool frequencies were reduced than pain frequencies were reduced in the entire population (p < 0.001), but there were no significantly difference in the subpopulation Groups 1, 3, 4, and 6 (p > 0.05). Multiple active ingredients and their mechanisms of actions to relieve IBS symptoms were identified. CONCLUSION: The outcomes in subpopulations may be different from those of the entire population, indicating that personalized formulas are important to achieve optimal outcomes; the active ingredients and innovative mechanisms identified in this study can be the candidates for developing new IBS drugs, and used to manage IBS, respectively. TRIAL REGISTRATION: NCT01641224 (www.ClinicalTrials.gov).
引用
- Wang Y, Fan H, Qi X, et al. Are personalized tongxie formula based on diagnostic analyses more effective in reducing IBS symptoms?-A randomized controlled trial. Complement Ther Med. 2018. PMID: 30219477. doi:10.1016/j.ctim.2018.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。